St. Louis School of Medicine: New Cell-Based Immunotherapy Offered for Melanoma
February 21, 2024
February 21, 2024
ST. LOUIS, Missouri, Feb. 21 (TNSres) -- The Washington University St. Louis School of Medicine issued the following news release:
* * *
FDA approved treatment via Accelerated Approval pathway
* * *
Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, is one of the first centers nationwide to offer a newly approved cell-based immunotherapy that targets melanoma.
With the . . .
* * *
FDA approved treatment via Accelerated Approval pathway
* * *
Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, is one of the first centers nationwide to offer a newly approved cell-based immunotherapy that targets melanoma.
With the . . .